## Edgar Filing: LIGAND PHARMACEUTICALS INC - Form 8-K

## LIGAND PHARMACEUTICALS INC

Form 8-K May 21, 2007

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

\_\_\_\_\_

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 15, 2007

LIGAND PHARMACEUTICALS INCORPORATED (Exact name of registrant as specified in its charter)

DELAWARE

(State or other jurisdiction of incorporation)

000-20720 (Commission File Number)

10275 SCIENCE CENTER DRIVE, SAN DIEGO, CALIFORNIA (Address of principal executive offices)

(858) 550-7500 (Registrant's telephone number, including area code)

77-0160744 (I.R.S. Employer Identification No.)

92121-1117 (Zip Code)

ITEM 5.02 DEPARTURE OF DIRECTORS OR PRINCIPAL OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF PRINCIPAL OFFICERS.

On May 15, 2007, Tod G. Mertes resigned as Vice President and Interim Chief Accounting Officer of Ligand Pharmaceuticals Incorporated (the "Company"), effective immediately.

## Edgar Filing: LIGAND PHARMACEUTICALS INC - Form 8-K

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

LIGAND PHARMACEUTICALS INCORPORATED

By: /s/ Charles S. Berkman Name: Charles S. Berkman Date : May 21, 2007

Title: Vice President, General Counsel & Secretary